Truffle Capital, a leading European venture capital firm committed to supporting the creation and development of innovative start-ups, is proud to announce the ongoing acquisition of Vexim, a leader inmini-invasive spine surgery, by Stryker Corporation for an amount (on a fully diluted basis) of 183 million Euros (20 € per share). For details of the acquisition, please refer exclusively to Vexim and Stryker press releases.
Truffle Capital, which co-founded Vexim in 2006 and has remained the company's lead investor ever since, has been involved in all of Vexim's structuring, management team building, R&D, development and commercial stages. Winner of the NYSE Euronext's best IPO award of 2012 (Euronext Growth: ALVXM), Vexim has successfully marketed its products in Europe, and is currently preparing, with an international clinical trial and subject to FDA clearance, the potential market launch of its SpineJack® product in the United States in 2018. Vexim will now join Stryker's"Interventional Spine" division.
According to Dr. Philippe Pouletty, Co-Founder and Managing Director of Truffle Capital, "Vexim's success story and its acquisition by Stryker highlight the dynamism of radical innovation in the French MedTech sector, along with the entrepreneur-investor role played by Truffle Capital."
Truffle Capital congratulates Vincent Gardès, CEO of Vexim, and his entire team, and thanks the company's co-investors, including Kreaxi and Bpifrance. Also co-founded by Truffle, Symetis, which specializes in transcatheter aortic valves, was acquired in early 2017 by Boston Scientific. An active investor in the MedTech field, Truffle Capital is also a co-founder and shareholder of the following companies: in the cardiovascular field, Carmat (total artificial heart), Epygon (transcatheter mitral valve), Kephalios (adjustable mitral ring), Kardiosis (endoprosthesis for aortic aneurysm); in urology, Myopowers (artificial urinary sphincter); and in interventional high intensity ultrasounds, Theraclion. The firm also supports lead investments in biotech companies, including Abivax and Pharnext.
For more information, please visit www.truffle.fr